Published by Josh White on 6th July 2023
(Sharecast News) - Cell engineering platform technology company MaxCyte announced a strategic platform licence (SPL) agreement with Lyell Immunopharma - a clinical-stage T-cell reprogramming company - on Thursday.
URL: http://www.digitallook.com/dl/news/story/33621560/...